<code id='074C89CDDA'></code><style id='074C89CDDA'></style>
    • <acronym id='074C89CDDA'></acronym>
      <center id='074C89CDDA'><center id='074C89CDDA'><tfoot id='074C89CDDA'></tfoot></center><abbr id='074C89CDDA'><dir id='074C89CDDA'><tfoot id='074C89CDDA'></tfoot><noframes id='074C89CDDA'>

    • <optgroup id='074C89CDDA'><strike id='074C89CDDA'><sup id='074C89CDDA'></sup></strike><code id='074C89CDDA'></code></optgroup>
        1. <b id='074C89CDDA'><label id='074C89CDDA'><select id='074C89CDDA'><dt id='074C89CDDA'><span id='074C89CDDA'></span></dt></select></label></b><u id='074C89CDDA'></u>
          <i id='074C89CDDA'><strike id='074C89CDDA'><tt id='074C89CDDA'><pre id='074C89CDDA'></pre></tt></strike></i>

          focus

          focus

          author:knowledge    Page View:918
          Adam's take main illustration
          Molly Ferguson/STAT

          It took Anavex Life Sciences seven months to finally acknowledge the failure of a late-stage clinical trial in Rett syndrome.

          The negative study outcome was never in doubt, so the only surprise from Tuesday’s announcement was the company’s lame attempt at damage control. Anavex is a serial dissembler of clinical trial results, so I was expecting better spin. Instead, management barely tried, which tells you the real results from the Rett study must be truly awful.

          advertisement

          Anavex shares fell 31% to $6 in early trading. The company’s only drug in clinical development, called blarcamesine, is a zero. Rett is the latest failure, following earlier study failures in Alzheimer’s disease and Parkinson’s disease. Yet even with Tuesday’s drop in share price, Anavex still carries a fully diluted market value of nearly $650 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Psychedelics group wrestles with new pharma identity
          Psychedelics group wrestles with new pharma identity

          OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

          read more
          Shionogi licenses Pompe disease therapy from Maze Therapeutics
          Shionogi licenses Pompe disease therapy from Maze Therapeutics

          MazeTherapeuticsCEOJasonColomaCourtesyAfterseeingitslastdealgobustinthefaceofregulatoryscrutiny,Maze

          read more
          Hollywood unions extend contract negotiations for actors
          Hollywood unions extend contract negotiations for actors

          1:36HollywoodwritersandtheirsupportersfromtheSAGAFTRAactors'unionwalkthepicketlineoutsideWarnerBrosS

          read more

          Medicare says breakthrough device reimbursement rule to come by summer

          AfederalrulethatcouldmakeMedicarereimbursementforbreakthroughdeviceseasierisslatedforearlysummer.Ado